drugset / Trial / NCT05201690
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers
RandomizedSequentialTriple-blindTreatment
Summary
This is a randomized, double-blinded, placebo-controlled, single-center phase I clinical trial. The objective of this study is to evaluate the safety, tolerability, pharmacokinetic profiles of VV116 tablets after multiple ascending doses administered orally to Chinese healthy volunteers.
Timeline
- Start
- 2021-12-14
- Primary completion
- 2022-01-19
- Completion
- 2022-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REMIDEVIR | Small molecule | 200 mg | Oral |
| Subject | REMIDEVIR | Small molecule | 400 mg | Oral |
| Subject | REMIDEVIR | Small molecule | 600 mg | Oral |
Indications
No indication recorded.